Lenograstim


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV/SC Neutropenia following bone marrow transplantation 150 mcg/m2/day via IV infusion over 30 min or via SC inj, started the day after transplantation. Max duration: 28 days. SC Chemotherapy-induced neutropenia 150 mcg/m2/day, started not less than 24 hr after completion of chemotherapy. Max duration: 28 days. Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation Monotherapy: 10 mcg/kg/day for 4-6 days. After myelosuppressive chemotherapy: 150 mcg/m2/day, started 1-5 days after completion of chemotherapy. Severe congenital neutropenia 150 mcg/m2 (5 mcg/kg) /day, may be increased up to 20 mcg/kg/day.
Dosage Details
Intravenous
Neutropenia following bone marrow transplantation
Adult: 150 mcg/m2 daily given via IV infusion over 30 min or via s SC inj, to be started the day after transplantation and continued until neutrophil count has stabilised. Max duration: 28 days.
Child: >2 yr Same as adult dose.

Subcutaneous
Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation
Adult: As monotherapy: 10 mcg/kg daily for 4-6 days. After myelosuppressive chemotherapy: 150 mcg/m2 daily, to be started 1-5 days after completion of chemotherapy and continued until neutrophil count has stabilised.

Subcutaneous
Chemotherapy-induced neutropenia
Adult: 150 mcg/m2 daily, to be started on the day (not less than 24 hr) after completion of chemotherapy and continued until neutrophil count has stabilised. Max duration: 28 days.
Child: >2 yr Same as adult dose.

Subcutaneous
Congenital neutropenia
Adult: Severe cases: 150 mcg/m2 (5 mcg/kg) daily, may be increased up to 20 mcg/kg daily. Monitor neutrophil level over 7-14 days. Dose may be reduced or given on alternate days according to response.
Child: >2 yr Same as adult dose.
Contraindications
Myeloid malignancy (e.g. acute myeloid leukaemia).
Special Precautions
Patient w/ congenital neutropenia, leukocytosis, history of pulmonary infiltrates or pneumonia, sickle cell disease. Severe renal or hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Malignant cell growth (e.g. acute myeloid leukaemia or abnormal cytogenetics), leukocytosis, splenomegaly. Rarely, splenic rupture, CV events (e.g. MI).
Nervous: Headache, asthenia.
GI: Buccal cavity infection/inflammatory disorder, diarrhoea, abdominal pain, vomiting, nausea.
Resp: Dyspnoea, hypoxia, haemoptysis.
Hepatic: Increased ALT, AST, alkaline phosphatase.
Haematologic: Thrombocytopenia, sickle cell crisis.
Musculoskeletal: Bone pain, myalgia, arthralgia.
Dermatologic: Alopecia, rash, cutaneous vasculitis, neutrophilic dermatoses.
Immunologic: Allergic reactions (e.g. anaphylaxis).
Others: Sepsis, infection site reaction, fever, pain, increased LDH.
Potentially Fatal: Capillary leak syndrome, pulmonary infiltration leading to resp failure or acute resp distress syndrome.
MonitoringParameters
Monitor CBC, spleen enlargement.
Drug Interactions
Increased risk of pulmonary toxicity w/ bleomycin, cyclophosphamide, methotrexate.
Action
Description: Lenograstim is a granulocyte colony stimulating factor (G-CSF) that belongs to cytokine group of biologically active proteins. It regulates cell differentiation and cell growth thus inducing increase in peripheral blood neutrophil count.
Pharmacokinetics:
Absorption: Absolute bioavailability: 30%.
Distribution: Volume of distribution: Approx 1 L/kg.
Metabolism: Metabolised in the liver into peptides.
Excretion: Via urine (1%, as unchanged drug). Elimination half-life: 3-4 hr.
Storage
Store below 30°C.
ATC Classification
L03AA10 - lenograstim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
References
Buckingham R (ed). Lenograstim. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/07/2017.

Joint Formulary Committee. Lenograstim (Recombitant Human Granulocyte-Colony Stimulating Factor; rHuG-CSF). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/07/2017.

Disclaimer: This information is independently developed by MIMS based on Lenograstim from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Granocyte 34
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in